Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method, By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global genome editing market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 22.9% from 2021 to 2028. Increasing implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years.

Furthermore, the development of CRISPR -based novel diagnostic tools to mitigate the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics arena.

Apart from this, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard developed Retron Library Recombineering (RLR) - a new gene-editing tool that enabled the performance of millions of genetic experiments simultaneously, thereby providing better editing rates.

Moreover, the market is witnessing intensified competition among the market players owing to the expanding applications of genome editing tools. There has been an increased focus on the highly adaptable CRISPR technology. For instance, in April 2021, Vertex Pharmaceuticals paid USD 900 million to CRISPR Therapeutics to develop, manufacture and commercialize CRISPR-Cas9 gene-edited therapy for beta-thalassemia and sickle-cell disease. Such initiatives are anticipated to propel market growth.

The expanding gene therapy marketspace has shown significant interest in gene manipulation technologies, thus augmenting the revenue growth. In April 2021, a genome editing consortium announced its plan to develop a new genome editing 'toolkit'. This is aimed to boost gene therapy development. The amount of USD 190 million was granted to the Somatic Cell Genome Editing Consortium for the development of genome editing methods and approaches.

Technology Insights

The CRISPR/Cas9 segment dominated the market and accounted for the largest revenue share of 40.2% in 2020. This technique has revolutionized the genome manipulation space with its technical advantages. The advantages include targeted gene disruption, recovery in a guide RNA-specific manner, and regulation. These advantages have accelerated the adoption of CRISPR/Cas9 technology across wider applications.

The clinical applications of CRISPR have been widely accepted. This is evident by the increasing number of ongoing clinical trials using gene-editing techniques for the treatment of a wide range of diseases such as cancer, AIDS, and genetic diseases. Apart from human health, this technology is witnessing increasing usage in agriculture and animal breeding applications.

The limitations of CRISPR technology have increased in applications of the TALEN technique in some hard-to-edit genomic regions. According to a study published in January 2021, TALEN is found to be a more suitable tool for compact DNA studies. Such studies would increase the adoption of the TALEN technique in research settings in the coming years.

Delivery Method Insights

The ex-vivo delivery method segment dominated the market and accounted for the largest revenue share of 57.2% in 2020. This can be attributed to the advantages offered by this mode type such as ease of control in DNA modification. The growing clinical trial pipeline that deploys genome editing tools has spurred the ex-vivo delivery segment growth with the increased usage of this delivery method.

On the other hand, the in-vivo gene delivery method accounted for lower revenue generation because of challenges that occurred during the process such as off-target effects. However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.

Application Insights

The developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront, accounting for the largest revenue share of 58.8% in 2020. This can be attributed to the rapidly growing field of gene and stem cell therapy. The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases. The clinical application segment dominated the market and accounted for the significant revenue share in 2020.

Furthermore, the CRISPR technology is widely being applied to enhance the productivity of CHO cell lines. These cell lines are prominently used in the production of large molecule therapeutics. Thus, with the application of the CRISPR tool, the biopharmaceutical marketspace is witnessing advancements consequently driving the market for genome editing.

Besides, genetic engineering, genome editing technologies have high potential growth in clinical applications such as diagnostics and therapy development. For instance, an ongoing clinical trial sponsored by Cellectis S.A. is aimed to evaluate the efficacy and safety of UCART123 in patients with R/R Acute Myeloid Leukemia. This therapy is based on TALEN gene-editing technology.

End-use Insights

The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 48.4% in 2020. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to the segment revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies.

For instance, in April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc signed a strategic collaboration and licensing agreement to address rare and serious diseases. Through this agreement, CANbridge Pharmaceuticals, Inc. gained rights to the latter company’s gene-editing platforms. Similarly, in October 2020, Scribe Therapeutics collaborated with Biogen for the development of CRISPR-based genetic medicines for neurological diseases such as Amyotrophic Lateral Sclerosis.

On the other hand, government research and academic institutes are anticipated to witness healthy growth in the near future owing to the increasing uptake of gene-editing technologies in university-level projects. Active engagement of research institutes further supplements the segment growth. For instance, research institutes such as Baylor College of Medicine, Rice University, and Whitehead Institute are actively involved in efforts to advance genome editing.

Mode Insights

The contract-based genome editing segment dominated the market and accounted for the largest revenue share of 51.9% in 2020. The high cost of associated infrastructure coupled with increasing collaborations between market entities has resulted in a significant market share of contract services in the global market. For instance, in September 2020, ERS Genomics and Applied StemCell, Inc. signed an agreement for the commercialization of genome editing services.

Similarly, in November 2020, Eli Lilly and the company collaborated with Precision BioSciences, Inc. to use the latter company’s proprietary ARCUS genome editing platform to develop potential in-vivo therapeutics for genetic disorders. Such collaborations have intensified the market competition leading to organic revenue growth.

Well-established companies such as Merck KGaA and Thermo Fisher Scientific are involved in providing custom vectors for cell line editing and engineering. Such services are anticipated to witness growth in the coming years, thereby fueling revenue growth. The rapidly growing demand from gene therapy market players would also propel the revenue generation for contract manufacturers.

Regional Insights

North America dominated the genome editing market and accounted for the largest revenue share of 38.4% in 2020. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the market in the region.

Furthermore, the increasing number of patents awarded to U.S.-based key players has also accelerated the uptake of these tools in the country leading to significant market growth. For instance, Merck KGaA recently announced that two patents of the company have been approved in the U.S. for CRISPR gene-editing technologies.

On the other hand, in Asia Pacific, the market is anticipated to witness the fastest growth rate throughout the forecast period. In November 2020, China announced its ten most significant advances in the agriculture sector, out of which one was gene-editing technology, thus representing the high market penetration of this space in the country.

Key Companies & Market Share Insights

Most of the players are undertaking licensing agreements with technology developers to enhance their market presence. For instance, in February 2021, Caribou Biosciences, Inc. and AbbVie signed a license agreement for the research and development of CAR-T therapy. Abbvie gained rights to use Caribou's CRISPR genome editing technology under this agreement.

Similarly, in December 2020, Takara Bio licensed CRISPR genome editing technology from Merck KGaA (Millipore Sigma). This agreement enhanced Takara’s stem cell service capabilities including the development of vectors. Also, in April 2021, Inscripta installed its Onyx CRISPR-based genome editing platform at the University of Liverpool. Such initiatives are expected to positively impact market growth. Some of the prominent players in the genome editing market include:

• Merck KGaA

• Cibus, Recombinetics, Inc.

• Sangamo

• Editas Medicine

• Precision Biosciences

• CRISPR Therapeutics

• Intellia Therapeutics, Inc.

• Caribou Biosciences, Inc.

• Cellectis S.A.

• AstraZeneca

• Takara Bio USA

• Horizon Discovery Group plc

• Integrated DNA Technologies, Inc.

• Egenesis Inc.

• GenScript

• New England Biolabs

• OriGene Technologies, Inc.

• Lonza

• Thermo Fisher Scientific, Inc.

Genome Editing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global genome editing market report on the basis of technology, delivery method, application, mode, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2017 - 2028)

  • Meganucleases

  • (CRISPR)/Cas9

  • TALENs/MegaTALs

  • ZFN

  • Others

• Delivery Method Outlook (Revenue, USD Million, 2017 - 2028)

  • Ex-vivo

  • In-vivo

• Mode Outlook (Revenue, USD Million, 2017 - 2028)

  • Contract

  • In-house

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Biotechnology and pharmaceutical companies

  • Academic and government research institutes

  • Contract research organizations

• Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Genetic Engineering

    • Cell line engineering

    • Animal genetic engineering

    • Plant genetic engineering

    • Others

  • Clinical Applications

    • Diagnostics

    • Therapy Development

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia